News | January 03, 2024
Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The plant is yet to start commercial operations
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Subscribe To Our Newsletter & Stay Updated
